|
| Press Releases |
|
 |
|
| Wednesday, May 9, 2018 |
|
|
Helsinn Group announces the launch of the IV formulation of AKYNZEO(R) (fosnetupitant/palonosetron) in the United States |
| Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the intravenous formulation of AKYNZEO(R) (a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) for injection has been launched in the United States by its U.S. subsidiary, Helsinn Therapeutics (U.S.), Inc.. more info >> |
|
| Friday, April 20, 2018 |
|
|
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO(R) (fosnetupitant/ palonosetron) in the United States |
| Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the U.S. Food and Drug Administration (FDA) has approved the intravenous formulation of AKYNZEO(R) (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing CINV. more info >> |
|
| Tuesday, April 17, 2018 |
|
|
Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy |
| Taiho Pharmaceutical Co., Ltd., a Japanese R&D-driven specialty pharma focused on oncology and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announce that they are collaborating on the development of an investigational highly-selective RET inhibitor TAS0286/HM05, being evaluated in non-small cell lung cancer and other carcinomas. more info >> |
|
| Wednesday, March 28, 2018 |
|
|
Helsinn Healthcare S.A.: Winners of the inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced |
| Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, today announced that Lorenzo Pradella of GreenBone Ortho, srl and Gitte Pedersen of Genomic Expression, Inc. have been chosen as winners of the first ever Lyfebulb-Helsinn Innovation Awards in Oncology. more info >> |
|
| Friday, March 2, 2018 |
|
|
Helsinn Healthcare S.A.: Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology |
| Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, today announce the names of the eleven companies launched by patient entrepreneurs who are chosen as finalists for the Lyfebulb-Helsinn Innovation Summit & Award in Oncology. more info >> |
|
| Tuesday, October 17, 2017 |
|
|
Helsinn Pharmaceuticals (Beijing) Co. Ltd. Opens Office in Shanghai, China |
| Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces the approval of Helsinn Pharmaceuticals (Beijing) Co. Ltd., Shanghai branch, on August 7, 2017 by the Shanghai Administration for Industry and Commerce with a 30-year term. The full address and contact details of the Shanghai branch are found at the end of this announcement. more info >> |
|
| Friday, September 9, 2016 |
|
|
Helsinn and PatientsLikeMe Announce Results of NSCLC Patient Survey on Weight Loss |
| Helsinn Therapeutics (U.S.) Inc., the pharmaceutical group focused on building quality cancer care, and patient network PatientsLikeMe have unveiled findings from an online survey that captured experiences and insights about unintended weight loss and its burden among 95 patients living with non-small cell lung cancer. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
SAP商業AI持續釋放數據價值 驅動企業韌性增長
Jun 13, 2025 13:10 HKT/SGT
|
|
|
Ria Money Transfer's New Approval Enables Digital Salary Payments for Malaysia's Migrant Workforce
Jun 13, 2025 13:00: JST
|
|
|
ARE Expands India Leadership, Strengthens Regional Role in Climate, Energy, and Food System Transition
Jun 13, 2025 12:46: JST
|
|
|
Ria Money Transfer's New Approval Enables Digital Salary Payments for Malaysia's Migrant Workforce
Jun 13, 2025 12:00 HKT/SGT
|
|
|
TRENDE Announces Strategic Capital and Business Alliance with Tokyu Land
Jun 13, 2025 13:00 JST
|
|
|
ARE Expands India Leadership, Strengthens Regional Role in Climate, Energy, and Food System Transition
Jun 13, 2025 11:46 HKT/SGT
|
|
|
JBM Healthcare Delivers Strong FY2025 Annual Results, Net Profit Surged 51.2% to HK$197.3 Million
Jun 12, 2025 21:07 HKT/SGT
|
|
|
健倍苗苗二零二五財年全年業績表現亮眼 純利飆升51.2%至1.97億港元
Jun 12, 2025 20:58 HKT/SGT
|
|
|
健倍苗苗二零二五财年全年业绩表现亮眼 纯利飙升51.2%至1.97亿港元
Jun 12, 2025 20:48 HKT/SGT
|
|
|
品質基石的守護者：檢測檢驗行業賦能高質量發展
Jun 12, 2025 18:28 HKT/SGT
|
|
|
质量基石的守护者：检测检验行业赋能高质量发展
Jun 12, 2025 18:19 HKT/SGT
|
|
|
NEFECON(R) and EVER001 Drive Synergistic Progress as Everest Medicines Advances
Jun 12, 2025 17:38: JST
|
|
|
NEFECON(R) and EVER001 Drive Synergistic Progress as Everest Medicines Advances
Jun 12, 2025 16:38 HKT/SGT
|
|
|
耐賦康(R)與EVER001協同發力 雲頂新耀推動腎病治療進入精準管理新階段
Jun 12, 2025 16:31 HKT/SGT
|
|
|
耐赋康(R)与EVER001协同发力 云顶新耀推动肾病治疗进入精准管理新阶段
Jun 12, 2025 16:26 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
